- WORX ripped higher in premarket trading (up ~52% to ~$0.44) and continued to spike after the open. Benzinga
- Intraday, the stock briefly more than doubled (ChartMill flagged WORX among the day’s biggest “gappers”). ChartMill
- No fresh company press release or SEC filing today as of publication; the most recent company updates were in October (Nasdaq compliance extension and a 3‑year contract renewal). SCWorx, Corp.
- Next known catalyst: SCWorx’s Annual Meeting on Dec. 8, 2025, where shareholders will vote on proposals including authorizing more shares and equity plans. SEC
What happened today
- Premarket momentum: WORX appeared on multiple “movers” dashboards before the bell, up ~52% around $0.44. Benzinga
- At-the-open follow‑through: During regular trading hours, ChartMill flagged WORX as a top “gapper,” noting a >100% intraday jump at one point. Micro‑cap names like WORX can see outsized percentage moves when liquidity floods in. ChartMill
Important context: There is no new company‑issued news stamped Nov. 6, 2025 on SCWorx’s investor relations page or the SEC feed. The last press releases were Oct. 14 (Nasdaq extension) and Oct. 6 (contract renewal). SCWorx, Corp.
Is there a catalyst?
October headlines still in focus
- Nasdaq minimum bid price extension: SCWorx said Nasdaq granted a second 180‑day window—until April 6, 2026—to regain $1.00 compliance. The company added it may implement a reverse split if needed. This was disclosed via an 8‑K and IR press release in mid‑October. SCWorx, Corp.
- Commercial update: On Oct. 6, SCWorx announced a three‑year renewal with an existing healthcare customer, lifting the contract value ~113% versus the prior term. SCWorx, Corp.
Today’s move looks technical
Given the absence of a new filing or press release today, the spike appears trading‑driven (momentum/technicals) rather than news‑driven. Micro‑floats can move quickly when liquidity concentrates.
Float & short interest (context):
- Yahoo Finance recently listed ~7.7M shares in the free float (provider estimates vary as outstanding shares change with conversions). Yahoo Finance
- MarketBeat’s late‑October read showed ~14.9% of float sold short, which can amplify swings. MarketBeat
What to watch next
1) Annual Meeting — Dec. 8, 2025
SCWorx’s definitive proxy (filed for the Dec. 8 meeting) asks shareholders to vote on several items, including:
- Increasing authorized shares from 45,000,000 to 155,000,000 (of which 150,000,000 would be common stock).
- Authorizing share issuances under Nasdaq Rule 5635(d) tied to previously issued and prospective warrants/convertible notes.
- Approving the 2025 Equity Incentive Plan.
- Ratifying the auditor (Astra Audit & Advisory, LLC).
Record date was Oct. 10, 2025; the proxy shows 12,105,650 common shares outstanding on that date and 39,810 preferred shares convertible into ~1.14M common shares. SEC
2) Nasdaq compliance clock — through April 6, 2026
SCWorx must achieve a $1.00+ closing bid for at least 10 consecutive trading days by the deadline to remain compliant; otherwise, it has indicated it may effect a reverse split within the range previously approved by shareholders. SCWorx, Corp.
Company snapshot (latest filed figures)
From SCWorx’s most recent 10‑Q for the quarter ended June 30, 2025 (filed Aug. 14):
- Six‑month revenue:$1.40M (vs. $1.55M YoY).
- Six‑month net loss:$2.38M (vs. $0.52M YoY), with management noting going‑concern uncertainties. SEC
Background note: In 2024, a former SCWorx CEO was convicted in a separate securities‑fraud case related to pandemic‑era test‑kit claims—context that still shades investor sentiment in micro‑cap healthcare data names. Reuters
Bottom line
- Today’s (Nov. 6) spike in WORX appears trader‑driven in the absence of fresh company news, amplified by small float/short dynamics and a flood of volume. MarketBeat
- Fundamental/structural watch‑items remain the Dec. 8 annual meeting proposals (share authorization & equity plan) and Nasdaq bid‑price compliance by April 6, 2026. SEC
This article is for informational purposes only and not investment advice. Always do your own research and consider consulting a licensed financial advisor.
